Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

16 treatments under study, led by Chemotherapy

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 2 (3)

Trial Status

Withdrawn2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00019097Phase 2Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma

NCT00085345Phase 2Withdrawn

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00112879Phase 2Withdrawn

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Showing all 3 trials

Research Network

Common Treatments

  • Chemotherapy2
  • Arsenic Trioxide2
  • Ascorbic Acid2
  • Melphalan2
  • Drug Resistance Inhibition1

Active Sponsors

  • National Cancer Institute (NCI)1
  • Oncotherapeutics1
  • The Cleveland Clinic1

Top Investigators

Related Conditions

  • Stage Ii Multiple Myeloma3
  • Stage Iii Multiple Myeloma3
  • Stage I Multiple Myeloma1

Activity Timeline